CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I

CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I

The treatment choice of differentiated thyroid cancer resistant to therapy 131I to be restricted just to systemic methods. Traditional chemotherapy demonstrated no clinically relevant effectiveness but high toxicity. With the introduction into clinical practice of multi-kinase inhibitor was able to...

Full description

Saved in:

Bibliographic Details
Main Authors:	P. A. Isaev, P. O. Rumyantsev, V. V. Polkin, A. A. Ilyin, D. Yu. Syomin, T. A. Agababyan, S. V. Vasilkov, V. S. Medvedev
Format:	Article
Language:	Russian
Published:	ABV-press 2015-04-01
Series:	Опухоли головы и шеи
Subjects:	the differentiated thyroid cancer resistant to therapy 131i decision multi-kinase inhibitor nexavar (sorafenib)
Online Access:	https://ogsh.abvpress.ru/jour/article/view/52
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Neoadjuvant target therapy of differentiated thyroid cancer (clinical observation)
by: P. A. Isaev, et al.
Published: (2017-04-01)

THE USE OF SORAFENIB (NEXAVAR) IN TREATMENT OF PATIENT WITH DISSEMINATED PARATHYROID CANCER: A CASE REPORT
by: V. A. Gorbunova, et al.
Published: (2017-04-01)

Approaches to conducting a physiologically relevant test (PRT) in the study of medicines containing substance IIc of the BCS subclass using sorafenib as an example
by: A. V. Suvorova, et al.
Published: (2024-09-01)

Side skin reactions of multikinase inhibitors in treatment of thyroid cancer
by: F. S. Sevryukov, et al.
Published: (2021-01-01)

HPLC-UV method development and validation for anticancer drug sorafenib and the co-prescribed drug dexamethasone: application to pharmacokinetic evaluation of sorafenib nanoformulations
by: Abdul Mateen, et al.
Published: (2025-04-01)

Radiation safety problems during the patient traveling by public transport after radiopharmaceutical therapy with 131I
by: A. V. Petryakova, et al.
Published: (2024-07-01)

Optimization algorithm for absorbed dose calculation during single intake of 131І to rats
by: I. P. Drozd, et al.
Published: (2015-12-01)

Sorafenib-Induced Spiny Follicular Hyperkeratosis: A Case Report with Review of Literature
by: Chandana Shajil, et al.
Published: (2024-04-01)

Familial Clinical Heterogeneity of Medullary Thyroid Cancer with Germline RET S891A Protooncogene Mutation: 7-year Follow-up with Successful Sorafenib Treatment
by: Sirmen Kızılcan Çetin, et al.
Published: (2025-09-01)

Successful two-stage operation for esophageal necrosis due to proton beam therapy followed by sorafenib in a case of large hepatocellular carcinoma
by: Eiji Higaki, et al.
Published: (2020-06-01)

<sup>131</sup>I-mIBG Therapy in the Management of High-Risk Neuroblastoma: A Retrospective Study from a Tertiary Level Hospital in South India
by: A.R. Vishnu, et al.
Published: (2025-02-01)

Decoding Drug Interactions: Character and Degree of Pharmacokinetic Interactions Between Telmisartan and Sorafenib or Donafenib in Rats
by: Li Y, et al.
Published: (2025-07-01)

Hematological parameters for a single oral intake of sodium iodide (Na131I) to the body of experimental rats
by: T. V. Tsyganok, et al.
Published: (2015-12-01)

Decitabine regulates the resistance of HCC to sorafenib through demethylation
by: Miao Zhang, et al.
Published: (2025-07-01)

Cancer-associated fibroblasts induce sorafenib resistance of hepatocellular carcinoma cells through CXCL12/FOLR1
by: Jiali Zhao, et al.
Published: (2023-12-01)

Implementing Neurosurgery and Cesium-131 Brachytherapy in Veterinary Medicine: A Veterinary Case Study with a Review of Clinical Usage of Cesium-131 for Brain Tumors in Human Patients and Opportunities for Translational Research
by: Isabelle F. Vanhaezebrouck, et al.
Published: (2025-04-01)

Co-Assembled Nanoparticles Comprising Sorafenib and Hederagenin Derivative for Enhanced Anti-Hepatic Fibrosis Activity
by: Lu M, et al.
Published: (2025-07-01)

Sorafenib tosylate inhibits autophagy, proliferation and migration of oral squamous cell carcinoma
by: XIONG Jianzhe, et al.
Published: (2024-08-01)

LINC00162 silencing enhances sorafenib sensitivity and inhibits thyroid cancer cells progression through modulation of MAPK signaling and apoptosis
by: Maryam Hejazi, et al.
Published: (2025-08-01)

Preparation of iodine-131 labeled Polyvinyl alcohol-collagen microspheres for radioembolization therapy of liver tumors
by: Yuhao Li, et al.
Published: (2025-03-01)

ZEB1 stratifies the response to Sorafenib and Mdivi-1 combination therapy in hepatocellular carcinoma
by: H. Freudenstein, et al.
Published: (2025-08-01)

Nasolacrimal Duct Obstruction Secondary to Radioactive Iodine-131 Therapy for Differentiated Thyroid Cancer
by: A. A. Trukhin, et al.
Published: (2022-12-01)

Identifying genes associated with Sorafenib resistance in hepatocellular carcinoma to develop risk model
by: Kuan He, et al.
Published: (2025-08-01)

Sorafenib-treated Th9 cells exhibit superior anti-tumor effect in lung metastasis
by: Fanli Yuan, et al.
Published: (2025-08-01)

The Radiosensitizing Effect of Tumor-Derived Microparticles Co-Loaded with Sorafenib and Gold Nanoparticles on Hepatocellular Carcinoma
by: Yu L, et al.
Published: (2025-04-01)

Emerging trends and knowledge networks in pan-cancer sorafenib resistance: a 20-year bibliometric investigation
by: Qiong Zhou, et al.
Published: (2025-07-01)

Comparative analysis of bevacizumab and sorafenib on the survival of retinal ganglion cells in the treatment of retinal diseases
by: Wungrak Choi, et al.
Published: (2025-08-01)

PHARMACOECONOMICAL RESEARCH OF THE USE OF SORAFENIB IN MALIGNANT TUMORS
by: M. Y. Frolov, et al.
Published: (2016-09-01)

ATF7IP inhibits Sorafenib-induced ferroptosis in hepatocellular carcinoma cells by inhibiting CYB5R2 transcription and stabilizing PARK7 protein
by: Yijie Su, et al.
Published: (2025-09-01)

Hematological and cytogenetic effects in the offspring of laboratory rats exposed to incorporated 131I
by: О. B. Ganzha, et al.
Published: (2019-06-01)

Dynamics of 131I accumulation and formation of doses in organs and tissues of the laboratory rats by prolonged oral intake
by: I. P. Drozd, et al.
Published: (2015-04-01)

Avaliação da Exposição Interna de trabalhadores em serviços de medicina nuclear através da análise de aerossóis contendo 131I
by: Luana Gomes Carneiro, et al.
Published: (2015-05-01)

Urinary Dopamine Levels Can Predict the Avidity of Post-Therapy [<sup>131</sup>I]MIBG Scintigraphy in Unresectable or Metastatic Pheochromocytomas and Paragangliomas: A Preliminary Clinical Study
by: Junki Takenaka, et al.
Published: (2025-01-01)

CRITERIA OF WELL-DIFFERENTIATED THYROID CARCINOMA RESISTANCE TO RADIOIODINE THERAPY
by: P. O. Rumyantsev, et al.
Published: (2015-04-01)

Use of the radiation environmental monitoring results for control of the atmospheric releases of iodine-131 by the facility
by: A. I. Kryshev, et al.
Published: (2023-06-01)

Sorafenib enhanced the function of myeloid-derived suppressor cells in hepatocellular carcinoma by facilitating PPARα-mediated fatty acid oxidation
by: Chunxiao Li, et al.
Published: (2025-01-01)

In vivo assessment of pharmacokinetic interactions of empagliflozin and henagliflozin with sorafenib: an animal-based study
by: Wenyu Du, et al.
Published: (2025-07-01)

LOW DOSE CYTARABINE PLUS SORAFENIB IN AN ELDERLY PATIENT WITH ACUTE MYELOID LEUKEMIA
by: Tural Mahmudov
Published: (2025-07-01)

Сytogenetic effects in the bone marrow of rats with long-term ingestion of 131I
by: О. A. Sova
Published: (2015-10-01)

Impact of extrathyroidal autoimmune diseases on clinical features and the efficacy of Iodine‐131 therapy in patients with differentiated thyroid cancer
by: Ya‐hong Long, et al.
Published: (2024-09-01)